Gilead Starts Two Phase III Trials of Remdesivir for COVID-19

Gilead Sciences has started two Phase III clinical trials of remdesivir in adults diagnosed with COVID-19. These randomized, open-label, multicenter studies will enroll approximately 1,000 patients at medical centers primarily in Asian countries. One study will randomize 400 patients with severe cases of COVID-19 to receive either five or 10 days of remdesivir. The second trial will randomize 600 patients with moderate disease to receive five or 10 days of remdesivir or standard of care alone. More details.... Stock Symbol: (NSDQ: GILD) Share this with colleagues: // //